The FDA on 25 January 2013 approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia...
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from FDA for its Abbreviated New...
New results from two Phase III clinical trials further establish the benefits of Tasigna (nilotinib), from Novartis, compared to Gleevec...
The pivatol Phase III IMPRES clinical trial showed that the investigational therapy QTI571 (imatinib), known as Gleevec and Glivec in...
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid...
The primary end point of the phase III PhALLCON study (NCT03589326) was met as first-line ponatinib (Iclusig) ,from Takeda and Incyte, plus reduced-intensity chemotherapy outperformed imatinib (Gleevec) for the treatment of patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL)
The FDA postponed a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review QT 1571 which is imatinib...
Pfizer Inc. has announced that the FDA has approved Bosulif (bosutinib), an Abl and Src kinase inhibitor, for the treatment...